The packed PD-(L)1 game just got another player — a low-profile biosimilars company looking to branch out with a $150M cash pact
After the majors lined up their PD-(L)1s, a low-profile biosimilars company has stepped up with the latest partnership as the next wave of checkpoints is about to hit a crowded shore.
Coherus BioSciences is dropping $150 million upfront for the rights to Junshi Biosciences’ toripalimab — China’s first homegrown anti-PD-1 monoclonal antibody to get marketing approval. The biotech joins the ranks of Eli Lilly, Novartis and EQRx, which all struck big PD-1 deals in the last year. The deals raise the possibility that long after becoming megablockbusters, Keytruda and Opdivo could see some price competition in the near future.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,500+ biopharma pros reading Endpoints daily — and it's free.